Short Course Program

Short courses will be presented on Sunday, September 24. Courses 1 and 2 will be presented in the morning concurrently and courses 3 and 4 will be presented concurrently in the afternoon. 

Short courses are offered at an additional fee for meeting registrants. Course attendees receive course materials electronically and a complimentary attendee lunch.

Short Course 1: Reaction Phenotyping – Methods and Regulatory Requirements for Identifying the Role of Phase 1 and Phase 2 Enzymes in Drug Disposition
Chair: Michael Sinz, Bristol-Myers Squibb

  • Reaction Phenotyping for CYP Enzymes
    Michael Sinz, Bristol-Myers Squibb
  • Reaction Phenotyping for non-CYP, Phase 1 Enzymes
    Tonika Bohnet, Biogen
  • Reaction Phenotyping for UGT Enzymes
    Michael Zientek, Takeda
  • Unusual Pathways of Drug Metabolism – Unexpected Reaction Phenotyping Findings
    Faraz Kazmi, Johnson & Johnson

Short Course 2: The Basics of Predicting Clearance Mechanisms for Human PK in Drug Discovery and Development and the Application of Extended Clearance Classification Systems
Chairs: Ayman El-Kattan, Pfizer and Yurong Lai, Bristol-Myers Squibb

  • Prediction of Metabolic Drug Clearance in Humans
    Nina Isoherranen, University of Washington
  • The Role of Hepatic Transporters in Drug Disposition and Elimination
    Kim Brouwer, University of North Carolina
  • The Application of BCS and BDDCS in Drug Discovery and Development
    Les Benet, University of California, San Francisco
  • The Utility of Extended Clearance Classification in Predicting Human Drug Clearance in Early Drug Discovery
    Ayman El-Kattan, Pfizer

      Short Course 3: Metabolism-Mediated Toxicity: Importance, Prediction, and Evaluation
      Chair: Amit S. Kalgutkar, Pfizer

      • Predicting Metabolism-Mediated Toxicities of Drug Candidates
        Amit S. Kalgutkar, Pfizer
      • How Reactive Metabolites Induce an Immune Response that Sometimes Lead to an Idiosyncratic Drug Reaction
        Jack Uetrecht, University of Toronto
      • Modeling Hepatic Drug Metabolism and Toxicity: Where are We Heading?
        Dominic Williams, AstraZeneca
      • Integrating DILI Hazards in Predicting Toxicity of Drug Candidates: Assessment and Management of Human Risk in the Pharmaceutical Industry
        Gerry Kenna, Drug Safety Consultant

        Short Course 4: Predicting Human Transporter-related Clearance and Drug-Drug Interactions (DDIs) as Currently Practiced in Regulatory Agencies and Industry
        Chairs, Ping Zhao and Yurong Lai, Bristol-Myers Squibb

        • Evaluation of Drug-Drug Interactions to Inform Drug Use
          Lei Zhang
        • Considerations of Communicating DDI Findings from Various Sources in US Prescription Information
          Joseph Grillo
        • Static and Dynamic Models to Predict Human Hepatic and Renal DDIs
          Manthena Varma, Pfizer
        • Case Studies for Evaluating DDIs Related to Renal Drug Transporters
          Kate Hillgren, Eli Lilly and Company